Life Sciences Tools and Services
Company Overview of GVK Biosciences Private Limited
GVK Biosciences Private Limited provides contract research services to pharmaceutical and biotechnology companies. The company provides bioinformatics services, including DNA and protein sequence analysis, protein structure analysis, homology modeling, biostatistics, data analysis using SAS/R, and microarray data analysis; chemoinformatics services, including molecular modeling studies, lead generation, virtual screening, ADME and toxicological property prediction, and crystal structure prediction; structural biology services, including structure determination, critical analysis of protein structures, protein-drug interactions, and protein-protein interactions; and KPO and custom curation se...
Plot No. 28 A
Founded in 2000
91 40 6692 9999
91 40 6692 9900
Key Executives for GVK Biosciences Private Limited
Vice Chairman and Managing Director
Senior Vice President of Discovery Chemistry
Head of the Biology SBU & Collaborative Research initiatives
Compensation as of Fiscal Year 2015.
GVK Biosciences Private Limited Key Developments
GVK Biosciences May Exit Clinical Trials
Jul 27 15
GVK Biosciences Private Limited is considering putting its clinical trials business on the block, in part or full, if market buzz is to be believed. According to people familiar with the development, GVK Biosciences is already in parleys to sell the business, which accounts for just 10% of its revenues.
Medivir AB Announces Partnership with GVK Biosciences Private Ltd
Jun 25 15
Medivir AB has announced a partnership with GVK Biosciences Private Ltd., or GVK BIO. The new partnership is designed to deliver enhanced efficiency and quality within its portfolio of research projects while over time reducing overall research costs and enhancing future cost flexibility. To ensure that its operations are run as efficiently as possible, Medivir has conducted a review of its Discovery Research operations. While committed to maintaining the current size of its discovery portfolio to deliver a constant flow of candidate drugs into its development pipeline, it has identified the opportunity to improve quality and efficiency through partnership with GVK BIO. The partnership will consolidate and strengthen all current out-sourced synthetic chemistry in a single facility at GVK BIO's Integrated Discovery Research Campus, where an addition of approximately 20 scientific staff will further accelerate the synthesis and testing of compounds. The company has also decided to exit the neuropathic pain area, following adverse findings in non-clinical safety studies of MIV-247, its cathepsin S inhibitor being developed for neuropathic pain. Development of this program has been terminated and future drug discovery efforts will be focused in the core areas of oncology and infectious diseases. As a result of the changes described, around ten scientific staff at Medivir facilities in the UK and Sweden will be made redundant.
Medivir AB Enters into Partnership with GVK Biosciences Private Limited to Deliver Enhanced Efficiency and Quality within its Portfolio of Research Projects
Jun 17 15
Medivir AB announced that it has entered into a partnership with GVK Biosciences Private Ltd. to deliver enhanced efficiency and quality within its portfolio of research projects, reduce the overall research costs and enhance future cost flexibility. The partnership will consolidate and strengthen all current outsourced synthetic chemistry projects in a single facility at GVK BIO's integrated discovery research campus at Hyderabad, where an addition of approximately 20 scientific staff will further accelerate the synthesis and testing of compounds. Medivir also announced reorganization within its discovery research department, increasing its focus within the core areas of oncology and infectious diseases. The company has decided to exit the neuropathic pain area, following adverse findings in non-clinical safety studies of MIV-247, its Cathepsin S inhibitor being developed for neuropathic pain. The development of this program has been terminated and future drug discovery efforts will be focused in the core areas of oncology and infectious diseases.
Similar Private Companies By Industry
Recent Private Companies Transactions